Novo Nordisk A/S (ADR) (NYSE:NVO)

CAPS Rating: 4 out of 5

Engaged in discovery, development, manufacturing and marketing of pharmaceutical products and has two business segments - diabetes care and biopharmaceuticals.

Recs

0
Player Avatar Notwage (< 20) Submitted: 3/22/2011 12:56:12 PM : Outperform Start Price: $120.71 NVO Score: +14.47

Strong company, great products, lots of potential since healthcare will make great strides in the coming decades.

Featured Broker Partners


Advertisement